Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 2:44 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 457–480 of 2,298 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Treatment Response Clear all

Conditions: Breast Cancer, HER2-positive Breast Cancer, Triple Negative Breast Cancer
Interventions: Neoadjuvant Chemotherapy, Radiation Therapy, MRI, Breast Cancer Surgery, Biopsy, Biospecimen collection; Drug · Radiation · Procedure
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Mycobacterium Avium-intracellulare Infection, HIV Infections
Interventions: Rifabutin; Drug
Lead sponsor: Pharmacia; Industry
Eligibility: 12 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Saint Davids, Pennsylvania

Conditions: Histologically-confirmed Malignancies
Interventions: [18F] FLT, PET/CT scans; Radiation · Device
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: Chickenpox
Interventions: Candidate varicella vaccine, Marketed varicella vaccine, MMR vaccine, Hepatitis A vaccine, PCV (pneumococcal conjugate vaccine) 13, PCV 20, Vaxneuvance; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Months to 15 Months
Enrollment: 911 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 13
States / cities: Tucson, Arizona • Huntington Park, California • Sherman Oaks, California + 10 more

Conditions: Anxiety
Interventions: PIPA; Behavioral
Lead sponsor: Adam Lewin; Other
Eligibility: 3 Years to 7 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: St. Petersburg, Florida

Conditions: Advanced Solid Tumor
Interventions: HS-110 (viagenpumatucel-L), HS-130; Biological
Lead sponsor: Heat Biologics; Industry
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Prostate Cancer
Interventions: cholecalciferol; Dietary Supplement
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years to 120 Years · Male only
Enrollment: 148 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Metastatic Breast Cancer
Interventions: Fresolimumab, Radiation Therapy; Drug · Radiation
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 2
States / cities: Los Angeles, California • New York, New York

Conditions: Healthy
Interventions: Osteopathic Manipulation, Placebo; Other
Lead sponsor: West Virginia School of Osteopathic Medicine; Other
Eligibility: 21 Years to 60 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Lewisburg, West Virginia

Conditions: Pompe Disease
Interventions: Rituximab, Miglustat; Drug
Lead sponsor: University of Florida; Other
Eligibility: Up to 65 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2017
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Alcohol Use Disorder, Alcohol Drinking, Alcohol Abuse, Alcohol Dependence
Interventions: Contingency Management, Computer Based Training for Cognitive Behavioral Therapy for AUD (CBT4CBT); Behavioral
Lead sponsor: Washington State University; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Spokane, Washington

Conditions: Major Depressive Disorder
Interventions: Duloxetine, Placebo; Drug
Lead sponsor: University of Utah; Other
Eligibility: 18 Years to 55 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Renal Cell Carcinoma
Interventions: MB-002; Biological
Lead sponsor: Argos Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 3
States / cities: Orange, California • Buffalo, New York • Chapel Hill, North Carolina

Conditions: Obsessive-Compulsive Disorder
Interventions: ACT plus ERP, ERP alone; Behavioral
Lead sponsor: Utah State University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 2
States / cities: Chapel Hill, North Carolina • Logan, Utah

Conditions: Early Stage Breast Cancer
Interventions: Aerobic Training; Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 21 Years to 80 Years · Female only
Enrollment: 152 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 2
States / cities: Hartford, Connecticut • New York, New York

Conditions: Acromegaly
Interventions: Octreotide capsules; Drug
Lead sponsor: Chiasma, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 146 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 18
States / cities: Birmingham, Alabama • Los Angeles, California • Stanford, California + 12 more

Conditions: Sepsis
Interventions: Intravenous GR270773- Phospholipid Emulsion, Placebo; Drug · Other
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 1,415 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 132
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 110 more

Conditions: Gastric Adenocarcinoma, Gastric Squamous Cell Carcinoma, Gastroesophageal Junction Adenocarcinoma, Metastatic Malignant Neoplasm in the Stomach, Stage IV Esophageal Adenocarcinoma AJCC v7, Stage IV Esophageal Squamous Cell Carcinoma AJCC v7
Interventions: External Beam Radiation Therapy, Laboratory Biomarker Analysis, Pembrolizumab; Radiation · Other · Biological
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2024
U.S. locations: 1
States / cities: Duarte, California

Conditions: Autism Spectrum Disorder
Interventions: Memantine, Placebo; Drug · Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 8 Years to 17 Years
Enrollment: 84 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Myelogenous Leukemia
Interventions: Imatinib, Nilotinib (AMN107); Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 36
States / cities: Tucson, Arizona • Anaheim, California • Baldwin Park, California + 32 more

Conditions: Melanoma (Skin)
Interventions: gp100 antigen, incomplete Freund's adjuvant, sargramostim, tyrosinase peptide; Biological
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2002
U.S. locations: 2
States / cities: Los Angeles, California • Ann Arbor, Michigan

Conditions: High Risk MDS
Interventions: Azacitidine, Azacitidine plus Deferasirox; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 6
States / cities: Little Rock, Arkansas • Duarte, California • Baltimore, Maryland + 3 more

Conditions: Multiple Endocrine Neoplasia Type 1, Pancreatic Neuroendocrine Carcinoma
Interventions: Computed Tomography Perfusion Imaging, Laboratory Biomarker Analysis, Ziv-Aflibercept; Radiation · Other · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 3
States / cities: Tampa, Florida • Houston, Texas

Conditions: Chronic Pain and Relapse Prevention
Interventions: Chronic pain therapeutic interactive voice response (TIVR) system; Behavioral
Lead sponsor: University of Vermont; Other
Eligibility: 18 Years and older
Enrollment: 158 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2012
U.S. locations: 1
States / cities: Burlington, Vermont

Search by objective public record fields.

Neoadjuvant Complete Response Customized Treatment Approach for Definitive Management of Breast Cancer

Rifabutin Therapy for the Prevention of Mycobacterium Avium Complex (MAC) Bacteremia in HIV Positive Patients With CD4 Counts = or < 200: Treatment IND Study

Serial FLT PET Imaging in Cancer Patients for Monitoring of Response to Therapy

A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine and a Marketed Measles, Mumps and Rubella Vaccine When Administered as Intramuscular Injection to Healthy Children 12 to 15 Months of Age

Modular Treatment for Preschool Anxiety

A Phase 1 Study of HS130 in Combination With Viagenpumatucel-L (HS110) in Patients With Solid Tumors

Vitamin D in Treating Patients With Prostate Cancer

Fresolimumab and Radiotherapy in Metastatic Breast Cancer

Biomarkers of the Response to Osteopathic Manipulation

Observational Study for Subjects With Pompe Disease Undergoing Immune Modulation Therapies

Virtual Incentive Treatment for Alcohol

Neurobiology of Treatment Responses in MDD

RNA-Loaded Dendritic Cell Cancer Vaccine

Combining Acceptance and Commitment Therapy With Exposure and Response Prevention to Enhance Treatment Engagement

Exercise Therapy to Improve Cardiovascular Health in Post-Menopausal Women After Treatment for Early Stage Breast Cancer

Comparison of Oral Octreotide Capsules to Injectable Somatostatin Analogs in Acromegaly

GR270773 In The Treatment Of Suspected Or Confirmed Gram-Negative Severe Sepsis In Adults

Pembrolizumab and Palliative Radiation Therapy in Treating Patients With Metastatic Esophagus, Stomach, or Gastroesophageal Junction Cancer

Behavioral and Neural Response to Memantine in Adolescents With Autism Spectrum Disorder

Nilotinib vs Imatinib in Adult Patients With Philadelphia (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)

Vaccine Therapy in Treating Patients With Stage II Melanoma That Can Be Removed by Surgery

Phase II Study to Evaluate Overall Response in Patients With Higher Risk Myelodysplastic Syndromes (MDS) Treated With Azacitidine With or Without Deferasirox.

Ziv-Aflibercept in Treating and Computed Tomography Perfusion Imaging in Predicting Response in Patients With Pancreatic Neuroendocrine Tumors That Are Metastatic or Cannot Be Removed by Surgery

A Telephone Feedback System for Prevention of Chronic Pain Relapse